Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Mereo BioPharma Group

DB:MAH
Snowflake Description

Mediocre balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MAH
DB
£24M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. The last earnings update was 202 days ago. More info.


Add to Portfolio Compare Print
  • Mereo BioPharma Group has significant price volatility in the past 3 months.
MAH Share Price and Events
7 Day Returns
8.4%
DB:MAH
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-90.2%
DB:MAH
-13.2%
DE Biotechs
-20.9%
DE Market
MAH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mereo BioPharma Group (MAH) 8.4% -39.3% -57.7% -90.2% -94.8% -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • MAH underperformed the Biotechs industry which returned -13.2% over the past year.
  • MAH underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
MAH
Industry
5yr Volatility vs Market

Value

 Is Mereo BioPharma Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Mereo BioPharma Group. This is due to cash flow or dividend data being unavailable. The share price is €0.181.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mereo BioPharma Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mereo BioPharma Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:MAH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in GBP £-0.43
AIM:MPH Share Price ** AIM (2020-04-03) in GBP £0.19
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mereo BioPharma Group.

DB:MAH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:MPH Share Price ÷ EPS (both in GBP)

= 0.19 ÷ -0.43

-0.44x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mereo BioPharma Group is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Mereo BioPharma Group is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Mereo BioPharma Group's expected growth come at a high price?
Raw Data
DB:MAH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.44x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
39.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Mereo BioPharma Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Mereo BioPharma Group's assets?
Raw Data
DB:MAH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in GBP £0.60
AIM:MPH Share Price * AIM (2020-04-03) in GBP £0.19
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:MAH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:MPH Share Price ÷ Book Value per Share (both in GBP)

= 0.19 ÷ 0.60

0.32x

* Primary Listing of Mereo BioPharma Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mereo BioPharma Group is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Mereo BioPharma Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Mereo BioPharma Group has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Mereo BioPharma Group expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
39.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Mereo BioPharma Group expected to grow at an attractive rate?
  • Mereo BioPharma Group's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Mereo BioPharma Group's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Mereo BioPharma Group's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:MAH Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:MAH Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 39.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:MAH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:MAH Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 230 -42 84 2
2023-12-31 85 -64 -1 2
2022-12-31 0 -56 -56 2
2021-12-31 0 -42 -46 2
2020-12-31 0 -39 -41 3
2020-04-06
2019-12-31 0 -46 -40 3
DB:MAH Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-06-30 -36 -31
2019-03-31 -29 -32
2018-12-31 -23 -32
2018-09-30 -30 -33
2018-06-30 -37 -33
2018-03-31 -34 -36
2017-12-31 -32 -39
2017-09-30 -31 -38
2017-06-30 -30 -36
2017-03-31 -30 -32
2016-12-31 -30 -28

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Mereo BioPharma Group's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Mereo BioPharma Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:MAH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Mereo BioPharma Group Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MAH Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 2.20 2.20 2.20 1.00
2023-12-31 0.70 0.70 0.70 1.00
2022-12-31 -0.50 -0.50 -0.50 1.00
2021-12-31 -0.40 -0.40 -0.40 1.00
2020-12-31 -0.38 -0.27 -0.50 2.00
2020-04-06
2019-12-31 -0.40 -0.40 -0.40 2.00
DB:MAH Past Financials Data
Date (Data in GBP Millions) EPS *
2019-06-30 -0.43
2019-03-31 -0.44
2018-12-31 -0.45
2018-09-30 -0.46
2018-06-30 -0.47
2018-03-31 -0.51
2017-12-31 -0.56
2017-09-30 -0.56
2017-06-30 -0.55
2017-03-31 -0.59
2016-12-31 -0.63

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Mereo BioPharma Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Mereo BioPharma Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mereo BioPharma Group has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Mereo BioPharma Group performed over the past 5 years?

  • Mereo BioPharma Group's last earnings update was 202 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mereo BioPharma Group's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mereo BioPharma Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Mereo BioPharma Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Mereo BioPharma Group's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Mereo BioPharma Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mereo BioPharma Group Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MAH Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 -31.26 12.56 23.76
2019-03-31 -31.65 12.53 23.23
2018-12-31 -32.03 12.50 22.70
2018-09-30 -32.54 11.54 23.38
2018-06-30 -33.04 10.56 24.06
2018-03-31 -35.92 10.63 29.34
2017-12-31 -38.80 10.70 34.61
2017-09-30 -37.60 10.24 34.73
2017-06-30 -36.41 9.52 34.85
2017-03-31 -32.40 10.51 29.71
2016-12-31 -28.39 11.62 24.56
2016-06-30 -29.35 16.27 17.66
2015-12-31 -14.63 9.26 6.53

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Mereo BioPharma Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Mereo BioPharma Group has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Mereo BioPharma Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Mereo BioPharma Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mereo BioPharma Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Mereo BioPharma Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mereo BioPharma Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mereo BioPharma Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Mereo BioPharma Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Mereo BioPharma Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mereo BioPharma Group Company Filings, last reported 9 months ago.

DB:MAH Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 59.03 19.73 36.12
2019-03-31 59.03 19.73 36.12
2018-12-31 32.77 21.48 27.54
2018-09-30 32.77 21.48 27.54
2018-06-30 47.15 20.91 36.91
2018-03-31 47.15 20.91 36.91
2017-12-31 62.48 20.75 52.54
2017-09-30 62.48 20.75 52.54
2017-06-30 74.04 1.94 56.58
2017-03-31 74.04 1.94 56.58
2016-12-31 79.26 3.13 53.58
2016-06-30 90.89 2.96 70.18
2015-12-31 35.74 0.00 12.25
  • Mereo BioPharma Group's level of debt (33.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Mereo BioPharma Group's debt level has increased without past 5-year debt data.
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Mereo BioPharma Group's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Mereo BioPharma Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mereo BioPharma Group has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Mereo BioPharma Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Mereo BioPharma Group dividends.
If you bought €2,000 of Mereo BioPharma Group shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Mereo BioPharma Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Mereo BioPharma Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:MAH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:MAH Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-06
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Mereo BioPharma Group has not reported any payouts.
  • Unable to verify if Mereo BioPharma Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Mereo BioPharma Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Mereo BioPharma Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Mereo BioPharma Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mereo BioPharma Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mereo BioPharma Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Mereo BioPharma Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Denise Scots-Knight
COMPENSATION £747,840
AGE 60
TENURE AS CEO 4.8 years
CEO Bio

Dr. Denise Scots-Knight, Ph.D. serves as President of OncoMed Pharmaceuticals, Inc. She serves as Director at Elanco Animal Health Incorporated since March 13, 2019. She has Co-founded Mereo BioPharma Group plc in 2015 and has been its Chief Executive Officer since July 1, 2015. Dr. Scots-Knight serves as Director at Cerimon Pharmaceuticals, Inc. She has been an Executive Director of Mereo BioPharma Group plc since July 29, 2015. She served as a Director at OncoMed Pharmaceuticals, Inc. since October 2008 until September 28, 2018. She served as Chief Executive Officer and Managing Partner at Phase4 Partners Limited from December 2010 until July 2015 and served as its Director. She previously served Managing Director at Nomura Principal Finance Group Europe. Dr. Scots-Knight served as the Chairman of Supervisory Board at Nabriva Therapeutics AG from 2007 until August 25, 2016 and served as its Member since 2007 until August 25, 2016. She served as Deputy Chairperson of Supervisory Board at Evotec (Göttingen) AG. She served as a Director of Intercell Ag. She served as Director of Albireo Pharma, Inc. since February 2008 until September 28, 2017. From April 2004 to December 2010, Dr. Scots-Knight was head of Nomura Phase4 Ventures, a venture capital affiliate of Nomura International plc, a leading Japanese financial institution. From January 1999 to March 2004, Dr. Scots-Knight served as head of Healthcare Private Equity at Nomura International plc. She served as a Director of ViaCell, Inc. from October 2003 to April 9, 2007. She served as a Director of Idenix Pharmaceuticals, Inc. from May 2003 to August 5, 2014. Dr. Scots-Knight holds a Ph.D. and a B.Sc. (Hons) degree with honors from the University of Birmingham and was a Fulbright scholar at the University of California, Berkeley. She also holds a diploma in Company Direction from the Institute of Directors.

CEO Compensation
  • Denise's compensation has increased whilst company is loss making.
  • Denise's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Mereo BioPharma Group management team in years:

4.8
Average Tenure
55
Average Age
  • The tenure for the Mereo BioPharma Group management team is about average.
Management Team

Denise Scots-Knight

TITLE
Co-Founder
COMPENSATION
£748K
AGE
60
TENURE
4.8 yrs

Charles Sermon

TITLE
Co-Founder
COMPENSATION
£543K
AGE
50
TENURE
5.3 yrs

Alastair MacKinnon

TITLE
Co-Founder & Chief Medical Officer
COMPENSATION
£538K
AGE
49
TENURE
5.3 yrs

John Richard

TITLE
Co-Founder & Head of Corporate Development
COMPENSATION
£508K
AGE
62
TENURE
5.3 yrs

Wills Hughes-Wilson

TITLE
Head of Patient Access & Commercial Planning
COMPENSATION
£100K
AGE
48
TENURE
2.2 yrs

Mike Wyzga

TITLE
Interim CFO & Director
AGE
64
TENURE
0.1 yrs

Fiona Bor

TITLE
Head of Intellectual Property

Ian Hodgson

TITLE
Head of Clinical Operations

Jackie Parkin

TITLE
Therapy Area Head of Respiratory Endocrinology

Jerome Dauvergne

TITLE
Head of Pharmaceutical Development
TENURE
2.9 yrs
Board of Directors Tenure

Average tenure and age of the Mereo BioPharma Group board of directors in years:

4.8
Average Tenure
63
Average Age
  • The tenure for the Mereo BioPharma Group board of directors is about average.
Board of Directors

Peter Fellner

TITLE
Independent Non-Executive Chairman
COMPENSATION
£100K
AGE
76
TENURE
4.8 yrs

Denise Scots-Knight

TITLE
Co-Founder
COMPENSATION
£748K
AGE
60
TENURE
4.8 yrs

Mike Wyzga

TITLE
Interim CFO & Director
AGE
64
TENURE
1 yrs

Peter James Bains

TITLE
Independent Non-Executive Director
COMPENSATION
£44K
AGE
62
TENURE
4.8 yrs

Paul Blackburn

TITLE
Independent Non-Executive Director
COMPENSATION
£48K
AGE
65
TENURE
4.5 yrs

Anders Ekblom

TITLE
Independent Non-Executive Director
COMPENSATION
£48K
AGE
65
TENURE
4.8 yrs

Kunal Kashyap

TITLE
Non-Executive Director
COMPENSATION
£40K
AGE
54
TENURE
4.8 yrs

Deepa Pakianathan

TITLE
Independent Non-Executive Director
AGE
54
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
25. Nov 19 Buy Richard Crispin Jones Individual 25. Nov 19 25. Nov 19 25,440 €0.45 €11,333
20. Nov 19 Buy Alastair MacKinnon Individual 19. Nov 19 19. Nov 19 12,879 €0.46 €5,864
14. Oct 19 Buy Peter Fellner Individual 11. Oct 19 11. Oct 19 25,500 €0.70 €17,582
04. Oct 19 Buy Alastair MacKinnon Individual 03. Oct 19 03. Oct 19 8,391 €0.67 €5,586
26. Sep 19 Buy Alastair MacKinnon Individual 25. Sep 19 25. Sep 19 3,313 €0.68 €2,245
24. Sep 19 Buy Alastair MacKinnon Individual 23. Sep 19 23. Sep 19 1,619 €0.69 €1,117
20. Sep 19 Buy Denise Scots-Knight Individual 19. Sep 19 19. Sep 19 13,500 €0.67 €8,995
16. Aug 19 Buy Charles Sermon Individual 15. Aug 19 15. Aug 19 6,355 €0.59 €3,744
16. Aug 19 Buy Denise Scots-Knight Individual 15. Aug 19 16. Aug 19 12,000 €0.59 €7,084
19. Jul 19 Buy Denise Scots-Knight Individual 17. Jul 19 18. Jul 19 10,000 €0.50 €5,001
01. May 19 Buy Alexandra Hughes-Wilson Individual 29. Apr 19 29. Apr 19 8,000 €1.38 €11,017
30. Apr 19 Buy Peter Fellner Individual 29. Apr 19 29. Apr 19 30,000 €1.48 €44,438
X
Management checks
We assess Mereo BioPharma Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mereo BioPharma Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a novel antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; MPH-966, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that has completed Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. The company also develops OMP-305B83 and OMP-313M32, which are anti-cancer therapeutic candidates in clinical development stage. Mereo BioPharma Group plc was founded in 2015 and is headquartered in London, the United Kingdom.

Details
Name: Mereo BioPharma Group plc
MAH
Exchange: DB
Founded: 2015
£26,847,882
124,507,857
Website: http://www.mereobiopharma.com
Address: Mereo BioPharma Group plc
1 Cavendish Place,
Fourth Floor,
London,
Greater London, W1G 0QF,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM MPH Ordinary Shares London Stock Exchange AIM Market GB GBP 09. Jun 2016
DB MAH Ordinary Shares Deutsche Boerse AG DE EUR 09. Jun 2016
NasdaqGM MREO SPON ADS EACH REP 4 ORD SHS Nasdaq Global Market US USD 24. Apr 2019
DB MAH0 SPON ADS EACH REP 4 ORD SHS Deutsche Boerse AG DE EUR 24. Apr 2019
BST MAH0 SPON ADS EACH REP 4 ORD SHS Boerse-Stuttgart DE EUR 24. Apr 2019
Number of employees
Current staff
Staff numbers
37
Mereo BioPharma Group employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 00:02
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/02/07
Last earnings filing: 2019/09/17
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.